Dr. Christos Fountzilas, MD, FACP
Claim this profileRoswell Park Cancer Institute
Studies Gastroesophageal Junction Adenocarcinoma
Studies Colorectal Cancer
18 reported clinical trials
35 drugs studied
Area of expertise
1Gastroesophageal Junction Adenocarcinoma
Stage IV
Stage III
BRCA1 positive
2Colorectal Cancer
Stage IV
Stage III
KRAS
Affiliated Hospitals
Clinical Trials Christos Fountzilas, MD, FACP is currently running
Pembrolizumab + Olaparib
for Pancreatic Cancer
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to some types of cancer, including pancreatic cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations.
Recruiting1 award Phase 237 criteria
Tinengotinib
for Bile Duct Cancer
This trial is testing an oral medication called Tinengotinib for patients with a specific type of bile duct cancer that has not responded to other treatments. The medication works by blocking a protein that helps cancer cells grow. The goal is to see if Tinengotinib can slow down or stop the cancer in these patients.
Recruiting2 awards Phase 3
More about Christos Fountzilas, MD, FACP
Clinical Trial Related5 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Christos Fountzilas, MD, FACP has experience with
- Irinotecan
- Pembrolizumab
- Bevacizumab
- TAS-102
- Talazoparib Tosylate
- Trifluridine And Tipiracil Hydrochloride
Breakdown of trials Christos Fountzilas, MD, FACP has run
Gastroesophageal Junction Adenocarcinoma
Colorectal Cancer
Cancer
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christos Fountzilas, MD, FACP specialize in?
Christos Fountzilas, MD, FACP focuses on Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer. In particular, much of their work with Gastroesophageal Junction Adenocarcinoma has involved Stage IV patients, or patients who are Stage III.
Is Christos Fountzilas, MD, FACP currently recruiting for clinical trials?
Yes, Christos Fountzilas, MD, FACP is currently recruiting for 8 clinical trials in Buffalo New York. If you're interested in participating, you should apply.
Are there any treatments that Christos Fountzilas, MD, FACP has studied deeply?
Yes, Christos Fountzilas, MD, FACP has studied treatments such as Irinotecan, Pembrolizumab, Bevacizumab.
What is the best way to schedule an appointment with Christos Fountzilas, MD, FACP?
Apply for one of the trials that Christos Fountzilas, MD, FACP is conducting.
What is the office address of Christos Fountzilas, MD, FACP?
The office of Christos Fountzilas, MD, FACP is located at: Roswell Park Cancer Institute, Buffalo, New York 14263 United States. This is the address for their practice at the Roswell Park Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.